@article{UBHD-68304777,
  author={Aldoss, Ibrahim and Nagorsen, Dirk},
  title={Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia},
  subtitle={bispecific T-cell engagers and chimeric antigen receptors},
  year={2017},
  pages={777-787},
  language={eng},
  issn={1476-5551},
  volume={31},
  number={4},
  note={Published: 28 December 2016 ; Gesehen am 13.09.2018},
  journal={Leukemia},
  doi={10.1038/leu.2016.391},
}
@article{UBHD-68450493,
  author={Goebeler, Maria-Elisabeth and Nagorsen, Dirk},
  title={Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-hodgkin lymphoma},
  subtitle={final results from a phase I study},
  year={2016},
  pages={1104-1111},
  language={eng},
  issn={1527-7755},
  volume={34},
  number={10},
  note={Gesehen am 05.11.2019},
  journal={Journal of clinical oncology},
  doi={10.1200/JCO.2014.59.1586},
}
@article{UBHD-68084698,
  author={Golay, Josée and Nagorsen, Dirk},
  title={A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy},
  year={2014},
  pages={4739-4747},
  language={eng},
  issn={1550-6606},
  volume={193},
  number={9},
  note={Gesehen am: 15.02.2017},
  journal={The journal of immunology},
  doi={10.4049/jimmunol.1401550},
}
@article{UBHD-68309707,
  author={Kantarjian, Hagop and Nagorsen, Dirk},
  title={Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia},
  year={2017},
  pages={836-847},
  language={eng},
  issn={1533-4406},
  volume={376},
  number={9},
  note={Gesehen am 27.09.2018},
  journal={The New England journal of medicine},
  doi={10.1056/NEJMoa1609783},
}
@article{UBHD-68326418,
  author={Papadopoulos, Kyriakos P. and Nagorsen, Dirk},
  title={First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors},
  year={2017},
  pages={5703-5710},
  language={eng},
  issn={1557-3265},
  volume={23},
  number={19},
  note={Gesehen am 08.11.2018},
  journal={Clinical cancer research},
  doi={10.1158/1078-0432.CCR-16-3261},
}
@article{UBHD-68344704,
  author={Stieglmaier, Julia and Benjamin, Jonathan and Nagorsen, Dirk},
  title={Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer},
  year={2015},
  pages={1093-1099},
  language={eng},
  issn={1744-7682},
  volume={15},
  number={8},
  note={Gesehen am 07.01.2019},
  journal={Expert opinion on biological therapy},
  doi={10.1517/14712598.2015.1041373},
}
@article{UBHD-68329805,
  author={Topp, Max S. and Nagorsen, Dirk},
  title={Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia},
  subtitle={a multicentre, single-arm, phase 2 study},
  year={2015},
  pages={57-66},
  language={eng},
  issn={1474-5488},
  volume={16},
  number={1},
  note={Gesehen am 19.11.2018 ; Published online December 16, 2014},
  journal={The lancet},
  doi={10.1016/S1470-2045(14)71170-2},
}
@article{UBHD-68448817,
  author={Viardot, Andreas and Nagorsen, Dirk},
  title={Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma},
  year={2016},
  pages={1410-1416},
  language={eng},
  issn={1528-0020},
  volume={127},
  number={11},
  note={Gesehen am 31.10.2019},
  journal={Blood},
  doi={10.1182/blood-2015-06-651380},
}
@article{UBHD-67778754,
  author={Wong, Ryan and Nagorsen, Dirk},
  title={Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells},
  year={2013},
  pages={1930-1938},
  language={eng},
  issn={1592-8721},
  volume={98},
  number={12},
  note={Gesehen am: 25.02.2015},
  journal={Haematologica, the hematology journal},
  doi={10.3324/haematol.2012.082248},
}
@article{UBHD-68329825,
  author={Zimmerman, Zachary and Maniar, Tapan and Nagorsen, Dirk},
  title={Unleashing the clinical power of T cells},
  subtitle={CD19/CD3 bi-specific T cell engager (BiTE) antibody construct blinatumomab as a potential therapy},
  year={2015},
  pages={31-37},
  language={eng},
  issn={1460-2377},
  volume={27},
  number={1},
  note={Gesehen am 19.11.2018 ; Advance access publication 19 September 2014},
  journal={International immunology},
  doi={10.1093/intimm/dxu089},
}